Navigation Links
Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe
Date:11/19/2009

MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that the leading driver of antibiotic selection in nosocomial pneumonia in Europe is broad-spectrum activity against gram-positive and gram-negative pathogens. Due to the variety of organisms that can cause nosocomial pneumonia, surveyed European physicians reveal that they look primarily for agents that provide appropriate coverage against common pathogens, particularly for empiric therapy.

"Nosocomial pneumonia is an extremely important indication in Europe because it is a significant cause of morbidity and mortality," stated Decision Resources Analyst Lisa Arias. "Prescribing for nosocomial pneumonia is heavily driven by the need for timely, effective empiric therapy, and European specialists cite Pseudomonas and MRSA as the most concerning pathogens in nosocomial pneumonia."

In the new report entitled Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia, surveyed European infectious disease specialists were highly receptive toward new antibiotics in late-stage development, including the two next-generation anti-MRSA cephalosporins (Johnson & Johnson/Basilea's ceftobiprole and Forest/AstraZeneca's ceftaroline) and the novel anti-MRSA lipoglycopeptide telavancin (Astellas/Theravance/Takeda's Vibativ). European physicians indicate that these therapies could be used in empiric therapy for nosocomial pneumonia when the pathogen is unknown and MRSA infection is suspected. Because European specialists foresee an increase in the incidence of MRSA nosocomial pneumonia in the next five years, these therapies may become useful additions to the antibiotic armamentarium, offering much needed novel treatment options for MRSA nosocomial pneumonia.

"There are limited therapeutic options to target resistant pathogens in nosocomial pneumonia, so there is high unmet need for new, effect
'/>"/>

SOURCE Decision Resources; Arlington Medical Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
2. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
6. Monetary gain and high-risk tactics stimulate activity in the brain
7. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
8. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
9. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
10. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
11. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Stemedica ... of clinical grade biological products as licensed by the State of California Food and Drug ... latest scientific discoveries at the 2009 World Stem Cell Summit. , ... San Diego, CA (PRWEB) Aug 27, 2009 -- ...
... , The statement below is from Pete Nicholas, Chairman ... employees and its Board of Directors. , , ... remarkably broad spectrum of issues. Foremost among them was his long and ... , He was a tireless advocate for patients, rights and for ...
... , CHICAGO, Aug. 26 Ajinomoto Food ... adding food product development capabilities. The Application Center North America ... , The ACNA mission is to develop and ... technology applications will be the initial focus of the Center: ...
Cached Biology Technology:Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 2Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 3Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries 4Boston Scientific Statement on the Passing of Senator Edward Kennedy 2
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... been accompanied by more years of perfect health, reveals new research ... . Indeed, a 20-year-old today can expect to live one ... a decade ago, even though life expectancy has grown. From ... 85 doubled, from about a 20 percent chance to a 40 ...
... BOSTON Boston University biology professor Richard Primack, ... completed an analysis of the changing arrival dates of ... Henry David Thoreau from the 1850,s. This research builds ... plants in Concord respond rapidly to temperature and are ...
... 2010 Elsevier ( www.elsevier.com ), a world-leading ... and services, today announced that as a result ... HealthMash, is now available on SciVerse Applications beta ... to provide insights to scientific researchers with relevant ...
Cached Biology News:We spend more time sick now than a decade ago 2We spend more time sick now than a decade ago 3WebLib develops application for Elsevier's SciVerse applications 2
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: